Literature DB >> 2446703

Selective antagonists of dopamine receptor subtypes differentially affect substance P levels in the striatum and substantia nigra.

A Oblin1, B Zivkovic, G Bartholini.   

Abstract

Repeated administration to rats of SCH 23390, a specific antagonist of the D-1 dopamine receptor, produced an increase in the substance P immunoreactivity in the striatum but not in the substantia nigra, whereas similar treatment with sulpiride, a specific D-2 dopamine receptor antagonist, reduced the nigral but not the striatal content of the peptide. When the two antagonists were given together, the SCH 23390-induced increase in striatal substance P was significantly reduced. The SCH 23390-induced increase in striatal substance P was curtailed by concomitant administration of progabide, a selective gamma-aminobutyric acid (GABA) receptor agonist. These results suggest the existence in the nigro-striatal complex of two different substance P-containing neurons which are differentially regulated by the dopamine receptor subtypes and indicate a role of GABA in the action of SCH 23390.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2446703     DOI: 10.1016/0006-8993(87)91314-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  3 in total

1.  Control of tachykinin-evoked acetylcholine release from rat striatal slices by dopaminergic neurons.

Authors:  J Alberch; E Arenas; E Pérez-Navarro; J Marsal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-11       Impact factor: 3.000

Review 2.  Dopamine D1 receptors, regulation of gene expression in the brain, and neurodegeneration.

Authors:  Jean Lud Cadet; Subramaniam Jayanthi; Michael T McCoy; Genevieve Beauvais; Ning Sheng Cai
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-11       Impact factor: 4.388

3.  Phenotypical characterization of the rat striatal neurons expressing the D1 dopamine receptor gene.

Authors:  C Le Moine; E Normand; B Bloch
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.